Enterprise Value
31.15M
Cash
139.2M
Avg Qtr Burn
-9.503M
Short % of Float
4.84%
Insider Ownership
6.27%
Institutional Own.
74.37%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WTX-330 (IL-2 INDUKINE™) Details Cancer, Solid tumor/s, Non-Hodgkin lymphoma | Phase 1 Data readout | |
WTX-124 +/- pembrolizumab (IL-2 INDUKINE™) Details Solid tumor/s, Cancer | Phase 1 Update |